Our study identifies FGF5 as a promising diagnostic biomarker for NPC recurrence risk and a potential therapeutic target, providing new insights into the molecular mechanisms underlying NPC recurrence and treatment resistance. Here, FGF5 is linked to nasopharyngeal carcinoma.